Difference between revisions of "Anagrelide (Agrylin)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "4 times per day" to "four times per day") |
m |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Interferes with maturation of platelets from megakaryocytes, phosphodiesterase inhibitor.<ref name="insert">[ | + | Class/mechanism: Interferes with maturation of platelets from megakaryocytes, phosphodiesterase inhibitor.<ref name="insert">[https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020333s017lbl.pdf Anagrelide (Agrylin) package insert]</ref><ref>[[Media:Anagrelide.pdf | Anagrelide (Agrylin) package insert (locally hosted backup)]]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
Revision as of 16:13, 18 May 2019
General information
Class/mechanism: Interferes with maturation of platelets from megakaryocytes, phosphodiesterase inhibitor.[1][2]
Route: PO
Extravasation: n/a
- Example of usage: Anagrelide (Agrylin) 0.5 mg PO four times per day or 1 mg PO twice per day, titrate to the lowest effective dose to maintain platelets below 600,000, maximum increase in dose of 0.5 mg/day every week (max dose: 10 mg/day, 2.5 mg in a single dose)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Anagrelide (Agrylin) patient drug information (Chemocare)[3]
- Anagrelide (Agrylin) patient drug information (UpToDate)[4]
Also known as
- Brand names: Agrylin, Xagrid